Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nephrectomy | 19 | 2021 | 1016 | 5.310 |
Why?
|
Lymph Node Excision | 17 | 2024 | 1303 | 4.990 |
Why?
|
Carcinoma, Transitional Cell | 7 | 2023 | 800 | 3.320 |
Why?
|
Urinary Bladder Neoplasms | 13 | 2023 | 2276 | 3.290 |
Why?
|
Kidney Neoplasms | 24 | 2021 | 4312 | 3.080 |
Why?
|
Carcinoma, Renal Cell | 21 | 2021 | 3218 | 3.020 |
Why?
|
Lymphatic Metastasis | 15 | 2022 | 2943 | 2.480 |
Why?
|
Prostatic Neoplasms | 28 | 2024 | 11345 | 2.410 |
Why?
|
Prostate | 14 | 2024 | 1793 | 2.040 |
Why?
|
Prostatectomy | 9 | 2024 | 1956 | 1.940 |
Why?
|
Cystectomy | 9 | 2023 | 697 | 1.930 |
Why?
|
Prostate-Specific Antigen | 7 | 2024 | 2529 | 1.480 |
Why?
|
Lymph Nodes | 8 | 2022 | 3486 | 1.370 |
Why?
|
Ureteral Neoplasms | 3 | 2019 | 110 | 1.130 |
Why?
|
Urinary Bladder | 6 | 2023 | 1166 | 0.960 |
Why?
|
Perioperative Period | 4 | 2019 | 264 | 0.960 |
Why?
|
Urology | 2 | 2021 | 423 | 0.950 |
Why?
|
Lymphocele | 1 | 2024 | 19 | 0.930 |
Why?
|
Peritoneum | 1 | 2024 | 224 | 0.840 |
Why?
|
Laparoscopy | 5 | 2024 | 2147 | 0.810 |
Why?
|
Biopsy | 10 | 2024 | 6771 | 0.770 |
Why?
|
Postoperative Complications | 9 | 2024 | 15697 | 0.740 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2022 | 187 | 0.720 |
Why?
|
Neoplasm Staging | 15 | 2023 | 11152 | 0.690 |
Why?
|
Pelvis | 2 | 2024 | 743 | 0.680 |
Why?
|
Pelvic Organ Prolapse | 2 | 2019 | 119 | 0.680 |
Why?
|
Penile Neoplasms | 1 | 2021 | 162 | 0.660 |
Why?
|
Quality Improvement | 3 | 2018 | 3836 | 0.630 |
Why?
|
Nomograms | 2 | 2021 | 238 | 0.600 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 1724 | 0.580 |
Why?
|
Colposcopy | 1 | 2018 | 150 | 0.570 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2019 | 2290 | 0.570 |
Why?
|
Early Detection of Cancer | 3 | 2024 | 3202 | 0.550 |
Why?
|
Gynecologic Surgical Procedures | 2 | 2019 | 304 | 0.520 |
Why?
|
Male | 66 | 2024 | 359744 | 0.510 |
Why?
|
Decision Support Techniques | 3 | 2024 | 2001 | 0.500 |
Why?
|
Hospital Costs | 2 | 2018 | 976 | 0.500 |
Why?
|
Surgical Flaps | 1 | 2024 | 1669 | 0.490 |
Why?
|
Aged | 45 | 2024 | 169152 | 0.490 |
Why?
|
Urinary Diversion | 1 | 2015 | 135 | 0.480 |
Why?
|
Kidney Calculi | 3 | 2015 | 468 | 0.480 |
Why?
|
Middle Aged | 48 | 2024 | 220352 | 0.460 |
Why?
|
Retrospective Studies | 34 | 2024 | 80372 | 0.460 |
Why?
|
Neoplasm Invasiveness | 6 | 2024 | 3618 | 0.450 |
Why?
|
Kidney Diseases | 2 | 2017 | 2093 | 0.450 |
Why?
|
Glomerular Filtration Rate | 4 | 2019 | 2180 | 0.450 |
Why?
|
Humans | 85 | 2024 | 760621 | 0.440 |
Why?
|
Brachytherapy | 1 | 2021 | 1238 | 0.440 |
Why?
|
Ureteral Diseases | 1 | 2013 | 65 | 0.430 |
Why?
|
Survival Analysis | 5 | 2020 | 10182 | 0.430 |
Why?
|
ABO Blood-Group System | 1 | 2015 | 369 | 0.430 |
Why?
|
Treatment Outcome | 22 | 2024 | 65017 | 0.420 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 5508 | 0.420 |
Why?
|
Morbidity | 4 | 2018 | 1765 | 0.400 |
Why?
|
Ultrasonography, Interventional | 2 | 2022 | 1502 | 0.400 |
Why?
|
Urinary Tract Infections | 3 | 2015 | 814 | 0.390 |
Why?
|
Nephrostomy, Percutaneous | 1 | 2012 | 82 | 0.380 |
Why?
|
Nephrolithiasis | 1 | 2012 | 114 | 0.360 |
Why?
|
Ureter | 1 | 2013 | 375 | 0.360 |
Why?
|
Urolithiasis | 1 | 2012 | 132 | 0.350 |
Why?
|
Ureteral Calculi | 1 | 2011 | 116 | 0.350 |
Why?
|
Risk Assessment | 7 | 2021 | 24123 | 0.340 |
Why?
|
Ureteral Obstruction | 1 | 2011 | 292 | 0.330 |
Why?
|
Gonadal Steroid Hormones | 1 | 2013 | 701 | 0.320 |
Why?
|
Prostatic Hyperplasia | 2 | 2024 | 530 | 0.320 |
Why?
|
Models, Statistical | 3 | 2019 | 5075 | 0.310 |
Why?
|
Databases, Factual | 3 | 2018 | 8035 | 0.310 |
Why?
|
Length of Stay | 3 | 2018 | 6479 | 0.300 |
Why?
|
Disease-Free Survival | 7 | 2019 | 6828 | 0.290 |
Why?
|
Proportional Hazards Models | 7 | 2020 | 12531 | 0.290 |
Why?
|
Animal Nutritional Physiological Phenomena | 1 | 2006 | 56 | 0.280 |
Why?
|
Medical Oncology | 1 | 2019 | 2313 | 0.280 |
Why?
|
Survival Rate | 9 | 2022 | 12808 | 0.270 |
Why?
|
Female | 39 | 2023 | 391270 | 0.270 |
Why?
|
Smoking | 1 | 2023 | 9073 | 0.260 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 8056 | 0.260 |
Why?
|
Propensity Score | 3 | 2020 | 1928 | 0.260 |
Why?
|
Attitude of Health Personnel | 2 | 2020 | 3865 | 0.260 |
Why?
|
Retroperitoneal Space | 2 | 2016 | 173 | 0.250 |
Why?
|
Radiology | 1 | 2019 | 2102 | 0.240 |
Why?
|
Magnetic Resonance Imaging | 8 | 2024 | 36290 | 0.230 |
Why?
|
Prognosis | 9 | 2022 | 29658 | 0.230 |
Why?
|
Combined Modality Therapy | 4 | 2019 | 8552 | 0.230 |
Why?
|
Transurethral Resection of Prostate | 1 | 2024 | 85 | 0.220 |
Why?
|
Hospitals | 1 | 2017 | 3928 | 0.220 |
Why?
|
Adult | 22 | 2022 | 219994 | 0.210 |
Why?
|
Administration, Intravesical | 1 | 2022 | 92 | 0.210 |
Why?
|
Lasers, Solid-State | 2 | 2024 | 175 | 0.210 |
Why?
|
Watchful Waiting | 3 | 2021 | 510 | 0.210 |
Why?
|
Logistic Models | 5 | 2018 | 13314 | 0.200 |
Why?
|
Stents | 2 | 2015 | 3314 | 0.200 |
Why?
|
United States | 12 | 2024 | 72461 | 0.200 |
Why?
|
Organ Size | 3 | 2021 | 2254 | 0.190 |
Why?
|
Inguinal Canal | 1 | 2021 | 71 | 0.190 |
Why?
|
Laser Therapy | 2 | 2024 | 1089 | 0.190 |
Why?
|
Kidney | 2 | 2021 | 7064 | 0.180 |
Why?
|
Circadian Rhythm | 1 | 2012 | 2571 | 0.180 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2022 | 3529 | 0.180 |
Why?
|
Aged, 80 and over | 9 | 2021 | 58995 | 0.180 |
Why?
|
Drosophila melanogaster | 2 | 2006 | 1710 | 0.180 |
Why?
|
Neoadjuvant Therapy | 2 | 2022 | 2821 | 0.170 |
Why?
|
Drosophila Proteins | 2 | 2006 | 1699 | 0.170 |
Why?
|
Forkhead Transcription Factors | 2 | 2006 | 1612 | 0.170 |
Why?
|
BCG Vaccine | 1 | 2022 | 371 | 0.170 |
Why?
|
Blood Transfusion | 2 | 2017 | 1328 | 0.170 |
Why?
|
Follow-Up Studies | 7 | 2019 | 39261 | 0.170 |
Why?
|
Liver Neoplasms | 1 | 2015 | 4319 | 0.160 |
Why?
|
Young Adult | 9 | 2019 | 58741 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2020 | 10344 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2015 | 9276 | 0.150 |
Why?
|
Urologic Neoplasms | 1 | 2021 | 320 | 0.150 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2022 | 1791 | 0.140 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6544 | 0.140 |
Why?
|
Adjuvants, Immunologic | 1 | 2022 | 1039 | 0.140 |
Why?
|
Indocyanine Green | 1 | 2019 | 236 | 0.140 |
Why?
|
Muscles | 1 | 2022 | 1581 | 0.140 |
Why?
|
Tomography, X-Ray Computed | 3 | 2017 | 20509 | 0.140 |
Why?
|
Evidence-Based Medicine | 2 | 2019 | 3696 | 0.130 |
Why?
|
Salvage Therapy | 1 | 2022 | 1268 | 0.130 |
Why?
|
Cohort Studies | 8 | 2022 | 41335 | 0.130 |
Why?
|
Renal Veins | 1 | 2016 | 102 | 0.130 |
Why?
|
Laparotomy | 1 | 2018 | 465 | 0.130 |
Why?
|
Access to Information | 1 | 2018 | 320 | 0.120 |
Why?
|
Costs and Cost Analysis | 1 | 2021 | 1677 | 0.120 |
Why?
|
Mass Screening | 2 | 2024 | 5423 | 0.120 |
Why?
|
Intraoperative Care | 2 | 2015 | 768 | 0.120 |
Why?
|
Economics, Hospital | 1 | 2017 | 212 | 0.120 |
Why?
|
Paraneoplastic Syndromes | 1 | 2016 | 155 | 0.120 |
Why?
|
Ureteroscopy | 1 | 2015 | 148 | 0.120 |
Why?
|
Delivery of Health Care | 3 | 2021 | 5325 | 0.110 |
Why?
|
Adolescent | 6 | 2019 | 87810 | 0.110 |
Why?
|
Vagina | 1 | 2019 | 837 | 0.110 |
Why?
|
Risk Factors | 7 | 2018 | 74359 | 0.110 |
Why?
|
Androgen Antagonists | 1 | 2022 | 1442 | 0.110 |
Why?
|
Time Factors | 5 | 2018 | 40165 | 0.110 |
Why?
|
Incidence | 2 | 2023 | 21392 | 0.110 |
Why?
|
Antineoplastic Agents | 2 | 2018 | 13630 | 0.110 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 5889 | 0.110 |
Why?
|
Vena Cava, Inferior | 1 | 2016 | 458 | 0.100 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12159 | 0.100 |
Why?
|
Urography | 1 | 2013 | 312 | 0.100 |
Why?
|
Molecular Imaging | 1 | 2019 | 818 | 0.100 |
Why?
|
Health Care Surveys | 1 | 2019 | 2435 | 0.100 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2013 | 345 | 0.090 |
Why?
|
Intraoperative Complications | 1 | 2017 | 1186 | 0.090 |
Why?
|
Lung Neoplasms | 1 | 2015 | 13262 | 0.090 |
Why?
|
Rupture, Spontaneous | 1 | 2011 | 356 | 0.090 |
Why?
|
Antibiotic Prophylaxis | 1 | 2015 | 643 | 0.090 |
Why?
|
Perioperative Care | 1 | 2018 | 1037 | 0.090 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7475 | 0.080 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2016 | 938 | 0.080 |
Why?
|
Postoperative Care | 1 | 2015 | 1479 | 0.080 |
Why?
|
Office Visits | 1 | 2013 | 597 | 0.080 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 11903 | 0.080 |
Why?
|
Decision Making | 2 | 2020 | 3925 | 0.080 |
Why?
|
Reoperation | 1 | 2017 | 4291 | 0.070 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2019 | 3340 | 0.070 |
Why?
|
Pilot Projects | 1 | 2019 | 8555 | 0.070 |
Why?
|
Venous Thrombosis | 1 | 2016 | 1299 | 0.070 |
Why?
|
Yeasts | 1 | 2006 | 279 | 0.060 |
Why?
|
Prevalence | 1 | 2022 | 15687 | 0.060 |
Why?
|
Fat Body | 1 | 2004 | 31 | 0.060 |
Why?
|
Holmium | 1 | 2024 | 29 | 0.060 |
Why?
|
Sarcoma | 1 | 2015 | 1786 | 0.060 |
Why?
|
Body Mass Index | 1 | 2021 | 12914 | 0.060 |
Why?
|
Aging | 2 | 2021 | 8651 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15289 | 0.050 |
Why?
|
Patient Readmission | 1 | 2017 | 3323 | 0.050 |
Why?
|
Disease Management | 1 | 2014 | 2514 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2012 | 6238 | 0.050 |
Why?
|
Nitrous Oxide | 1 | 2023 | 166 | 0.050 |
Why?
|
Disease Progression | 2 | 2017 | 13502 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2013 | 2283 | 0.050 |
Why?
|
Research Design | 1 | 2018 | 6180 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2019 | 7850 | 0.050 |
Why?
|
Thrombosis | 1 | 2016 | 3052 | 0.050 |
Why?
|
Sepsis | 1 | 2015 | 2592 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 14660 | 0.050 |
Why?
|
Insulin | 2 | 2006 | 6597 | 0.050 |
Why?
|
Mitochondrial Proteins | 1 | 2006 | 979 | 0.050 |
Why?
|
Insurance, Health | 2 | 2023 | 2501 | 0.040 |
Why?
|
Lidocaine | 1 | 2023 | 538 | 0.040 |
Why?
|
5-alpha Reductase Inhibitors | 1 | 2021 | 117 | 0.040 |
Why?
|
Marital Status | 1 | 2022 | 433 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15840 | 0.040 |
Why?
|
Venous Thromboembolism | 1 | 2013 | 1864 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 13981 | 0.040 |
Why?
|
Nephrons | 1 | 2020 | 168 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2016 | 22053 | 0.040 |
Why?
|
Ablation Techniques | 1 | 2021 | 248 | 0.040 |
Why?
|
Insurance | 1 | 2019 | 114 | 0.040 |
Why?
|
Germany | 1 | 2020 | 873 | 0.040 |
Why?
|
Sacrum | 1 | 2019 | 277 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2015 | 7408 | 0.040 |
Why?
|
Prospective Studies | 3 | 2023 | 54303 | 0.030 |
Why?
|
Anesthetics, Local | 1 | 2023 | 1001 | 0.030 |
Why?
|
Longevity | 1 | 2004 | 1050 | 0.030 |
Why?
|
SEER Program | 1 | 2022 | 1530 | 0.030 |
Why?
|
Coloring Agents | 1 | 2019 | 562 | 0.030 |
Why?
|
Transcription Factors | 2 | 2006 | 12103 | 0.030 |
Why?
|
Technetium | 1 | 2016 | 321 | 0.030 |
Why?
|
Energy Metabolism | 1 | 2006 | 2869 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2016 | 4902 | 0.030 |
Why?
|
Preoperative Care | 1 | 2024 | 2256 | 0.030 |
Why?
|
Age Factors | 1 | 2011 | 18416 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3441 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2021 | 2651 | 0.030 |
Why?
|
Endoscopy | 1 | 2024 | 1838 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2012 | 20080 | 0.030 |
Why?
|
Urinalysis | 1 | 2015 | 368 | 0.030 |
Why?
|
Child | 1 | 2021 | 79806 | 0.030 |
Why?
|
Oxygen | 1 | 2023 | 4193 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2013 | 680 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2006 | 18957 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2006 | 9411 | 0.020 |
Why?
|
Urologic Surgical Procedures | 1 | 2013 | 309 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2023 | 12427 | 0.020 |
Why?
|
Pain | 1 | 2023 | 5066 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 5201 | 0.020 |
Why?
|
Escherichia coli Infections | 1 | 2011 | 523 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2803 | 0.020 |
Why?
|
Lasers, Gas | 1 | 2008 | 94 | 0.020 |
Why?
|
Radiosurgery | 1 | 2016 | 1343 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3844 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9716 | 0.010 |
Why?
|
Insect Hormones | 1 | 2004 | 73 | 0.010 |
Why?
|
Genes, Insect | 1 | 2004 | 264 | 0.010 |
Why?
|
Immunotherapy | 1 | 2018 | 4642 | 0.010 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2004 | 412 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2017 | 4360 | 0.010 |
Why?
|
Self Report | 1 | 2013 | 3711 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2017 | 3388 | 0.010 |
Why?
|
Signal Transduction | 1 | 2004 | 23376 | 0.010 |
Why?
|
Societies, Medical | 1 | 2013 | 3905 | 0.010 |
Why?
|
Internet | 1 | 2013 | 3078 | 0.010 |
Why?
|
Receptor, Insulin | 1 | 2004 | 836 | 0.010 |
Why?
|
Organ Specificity | 1 | 2004 | 1955 | 0.010 |
Why?
|
Escherichia coli | 1 | 2011 | 4219 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 2004 | 1115 | 0.010 |
Why?
|
Brain | 1 | 2004 | 26951 | 0.010 |
Why?
|
Animals | 2 | 2006 | 167963 | 0.010 |
Why?
|
Stress, Physiological | 1 | 2004 | 1398 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2013 | 25942 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2004 | 12766 | 0.010 |
Why?
|
Neurons | 1 | 2004 | 9426 | 0.000 |
Why?
|
Concepts
(245)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(39)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_